What’s Next At Dr Reddy’s: Biologics CDMO, Cell And Gene Therapy Push
Executive Summary
Indian firms are getting their act together in areas like cell and gene therapy, with Dr Reddy’s aiming big and readying a facility alongside an alliance with a Chinese firm for a CAR-T therapy. The company is also doubling down in contract development and manufacturing, with an eye on opportunities in biologics.
You may also be interested in...
Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value
A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.
India's ImmunoACT Gears To Deliver CAR-T Therapy At Close To Transplant-Like Prices
ImmunoACT gets go-ahead in India for its CD19-targeted CAR-T cell therapy, which reported low toxicity and the absence of neurotoxicities in clinical trials. The product will come at a huge price differential compared to on-market therapies, offering new hope to several patients.
Sun Pharma Chief: We Are Not 'All In' In Biologics
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.